Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSAn Endocrine Reviews paper argues that GLP-1 and orexin, two peptide systems usually treated separately, are dysregulated together in long COVID and chronic fatigue. The therapeutic implication: combine GLP-1 drugs with orexin-targeting medication.
A 173,216-patient cohort with type 2 diabetes and pre-existing diabetic retinopathy showed GLP-1 users had lower progression to proliferative retinopathy (HR 0.78), retinal vein occlusion (HR 0.70), and neovascular glaucoma (HR 0.65). NAION risk was null (HR 0.88, CI 0.54-1.44).
Boehringer Ingelheim's Phase 3 SYNCHRONIZE-1 trial cleared its 76-week primary endpoint visit, with topline expected H1 2026. Survodutide is a GLP-1/glucagon dual agonist co-developed with Zealand Pharma, positioning to enter the obesity drug market behind semaglutide and tirzepatide.
Eli Lilly reports Q1 on April 30 with Foundayo's slow first two weeks (3,707 scripts vs Wegovy pill's 18,410 at the same week) under scrutiny. Novo follows May 6 with guided 5-to-13% sales decline. Goldman models Lilly's oral GLP-1 at 60% of the daily-oral segment by 2030 versus Novo at 21%.
Novo Nordisk's PIONEER TEENS Phase 3a trial in 132 kids aged 10 to 17 with type 2 diabetes cut HbA1c by 0.83 percentage points more than placebo at 26 weeks. Filing for label expansion is planned for H2 2026. It would be the first oral GLP-1 receptor agonist in this age group.
POTFlow, a flow-matching generative model conditioned on a known lead peptide, designed candidates targeting ATP5A in glioblastoma. The peptides selectively cut tumor cell viability and prolonged survival in patient-derived xenograft mice, closing the design-to-validation loop on a hard cancer target.
Crinetics Pharmaceuticals' CRN09682 entered Phase 1/2 BRAVESST2 trials this month. It pairs a small-molecule SST2 agonist with monomethyl auristatin E and targets the same receptor as Lutathera and Perspective Therapeutics' alpha-PRRT, trading peptide selectivity for small-molecule manufacturing simplicity.
Coracle Research published a 50-page defensive disclosure on April 25 covering an oral peptide tablet architecture for seven metabolic peptides, including tirzepatide and retatrutide. Predicted bioavailability runs 2 to 7 times Rybelsus. The publication exists specifically to make the architecture unpatentable.
RoboChem-Flex, a self-driving chemistry lab built from 3D-printed parts, was published in Nature Synthesis at a $5,000 hardware cost. The same week, a hobbyist used Claude Opus to sequence their own genome at home for around the same money. Both signal the same trend: the wet-lab gate is opening on the same arc that opened machine learning.
A Heart Rhythm cohort of 12,812 patients found GLP-1 therapy reduced atrial fibrillation incidence (HR 0.67) and mortality (HR 0.34) versus matched controls. The protective effect persisted in patients who gained weight on therapy. Only semaglutide reached statistical significance, and the AF benefit took two years to appear.
Icotrokinra (Icotyde) is a macrocyclic 13-amino-acid peptide that blocks the IL-23 receptor at picomolar affinity. FDA approved March 18 for plaque psoriasis. Oral bioavailability comes from molecular engineering, not an absorption enhancer.
Vosoritide, the C-type natriuretic peptide analog approved for achondroplasia, lifts growth velocity by partially overriding FGFR3. A new review argues it also affects bone density, callus consolidation, and medullary canal anatomy in children going through limb lengthening.
A JAAD Case Reports paper attributes drug-induced hypersensitivity syndrome to a naturally-occurring GLP-1 mimetic. The finding lands as the FDA reviews broader access to peptides that supplement marketing frames as natural.
Bicycle Therapeutics' EphA2 BIA, a gallium-68-labeled bicyclic peptide, lit up liver, bone, lymph node, and peritoneal metastases across AACR 2026's first-in-human pancreatic cancer cohort.
CVS/Aetna and UnitedHealth declined to join BALANCE, the insurer-funded Medicare obesity pilot. CMS pivoted: the federal government now directly funds GLP-1 coverage for seniors through the end of 2027.